Gilead Sciences FY2026 EPS Estimate Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised Gilead Sciences' FY2026 earnings per share (EPS) estimate down from $9.40 to $9.05, while maintaining an "Overweight" rating and a price target of $125.00.
• Gilead reported a quarterly EPS of $2.01, exceeding analysts' expectations of $1.96, with revenue of $7.08 billion, which was above the forecast of $6.95 billion.
• The company announced a quarterly dividend of $0.79 to be paid on September 29th, which reflects an annualized dividend yield of 2.7%.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities research analysts at Cantor Fitzgerald decreased their FY2026 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings per share of $9.05 for the year, down from their previous forecast of $9.40. Cantor Fitzgerald has a "Overweight" rating and a $125.00 price target on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The business's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.01 earnings per share.

Other equities research analysts have also recently issued reports about the company. UBS Group increased their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Finally, Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $114.82.

Gilead Sciences Price Performance

Gilead Sciences stock traded down $0.66 during midday trading on Friday, hitting $118.36. 1,424,096 shares of the company's stock were exchanged, compared to its average volume of 8,318,821. The stock has a 50-day moving average price of $111.76 and a two-hundred day moving average price of $108.16. Gilead Sciences has a 52-week low of $72.89 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market cap of $146.86 billion, a P/E ratio of 23.61, a PEG ratio of 0.74 and a beta of 0.33.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director directly owned 8,920 shares of the company's stock, valued at $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the sale, the chief financial officer directly owned 162,610 shares of the company's stock, valued at $18,054,588.30. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $8,734,625 over the last quarter. Company insiders own 0.27% of the company's stock.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences during the 1st quarter worth about $25,000. Activest Wealth Management raised its holdings in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. GoalVest Advisory LLC raised its holdings in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences in the second quarter valued at $27,000. Finally, Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences in the first quarter valued at $29,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.